PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
A New Set-up of Vanishing Antibodies: A Biennial Follow-up of Three Different Clients’ Humoral Responses Against Sars-Cov-2 After Systemic Vaccination in an Oncology Hospital in Poland
Version 1
: Received: 5 October 2022 / Approved: 6 October 2022 / Online: 6 October 2022 (08:42:11 CEST)
Version 2
: Received: 29 November 2022 / Approved: 1 December 2022 / Online: 1 December 2022 (10:22:30 CET)
Kosiorek, P.; Stróż, S.; Hryniewicz, A.; Kazberuk, D.E.; Milewski, R.; Bartoszewicz, K.; Borkowska, M.J.; Stasiak‐Barmuta, A. A New Set‐up of Vanishing Antibodies: A Biennial Follow‐up of Five Different Clients’ Humoral Responses against SARS‐CoV‐2 after Systemic Vaccination in an Oncology Hospital in Poland. Health Science Reports 2023, 6, doi:10.1002/hsr2.1172.
Kosiorek, P.; Stróż, S.; Hryniewicz, A.; Kazberuk, D.E.; Milewski, R.; Bartoszewicz, K.; Borkowska, M.J.; Stasiak‐Barmuta, A. A New Set‐up of Vanishing Antibodies: A Biennial Follow‐up of Five Different Clients’ Humoral Responses against SARS‐CoV‐2 after Systemic Vaccination in an Oncology Hospital in Poland. Health Science Reports 2023, 6, doi:10.1002/hsr2.1172.
Kosiorek, P.; Stróż, S.; Hryniewicz, A.; Kazberuk, D.E.; Milewski, R.; Bartoszewicz, K.; Borkowska, M.J.; Stasiak‐Barmuta, A. A New Set‐up of Vanishing Antibodies: A Biennial Follow‐up of Five Different Clients’ Humoral Responses against SARS‐CoV‐2 after Systemic Vaccination in an Oncology Hospital in Poland. Health Science Reports 2023, 6, doi:10.1002/hsr2.1172.
Kosiorek, P.; Stróż, S.; Hryniewicz, A.; Kazberuk, D.E.; Milewski, R.; Bartoszewicz, K.; Borkowska, M.J.; Stasiak‐Barmuta, A. A New Set‐up of Vanishing Antibodies: A Biennial Follow‐up of Five Different Clients’ Humoral Responses against SARS‐CoV‐2 after Systemic Vaccination in an Oncology Hospital in Poland. Health Science Reports 2023, 6, doi:10.1002/hsr2.1172.
Abstract
The humoral response of the COVID-19 vaccine varies from person to person. It largely depends on prior SARS-CoV-2 infection, obtaining an adequate immune response, and leaving a trace of changing antibody concentration over time. We retrospectively analyzed three clinical cases from selected patients and employees of the oncology hospital. All mild COVID-19 convalescents received the BNT162b2-Comirnaty mRNA vaccine three times. The levels of SARS-CoV-2 IgM- and IgG-specific antibodies, as well as S-RBD antibodies, were analyzed for approximately two years. The concentration of antibodies was assessed in the laboratory using the chemiluminescent immunoassay CLIA, MAGLUMI. Results: (1) Active autoimmune disease stabilized the level of IgG-specific antibodies after systemic mRNA vaccination for at least six months. (2) Post-vaccination IgG and S-RBD levels decreased when vaccination was performed within three months of onset. (3) The booster dose (third dose) administered only increased the S-RBD antibody levels. Declining IgG-specific antibodies were observed. (4) The S-RBD IgG levels were not correlated with the SARS-CoV-2 IgG levels in the vaccinated convalescents. (5) Subsequent reinfection with SARS-CoV-2 after vaccination three times released a more significant specific antibody response. Based on the collected data, we suggest that monitoring S-RBD antibodies is sensitive but not equivalent to a specific humoral response for SARS-CoV-2 IgG. We suggested that administering at least three doses of the mRNA vaccine should serve as the basis for immunization. The three-month interval may be the best alternative to an immunization schedule for non-immunocompromised people.
Medicine and Pharmacology, Pulmonary and Respiratory Medicine
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.